BC Week In Review | Oct 3, 2016
Company News

Cumberland Pharmaceuticals Inc sales and marketing update

Cumberland launched Ethyol amifostine in the U.S. to treat xerostomia in postoperative radiation of head and neck cancer and cumulative renal toxicity in ovarian cancer patients. In May, Cumberland acquired exclusive commercialization rights to the...
BC Week In Review | Jul 4, 2011
Company News

Pinnacle Biologics, University of Chicago deal

Pinnacle's Pinnacle Oncology LLC subsidiary acquired worldwide rights to use the university's long site life cycle technology to develop amifostine as a genomic stabilizing agent. Pinnacle plans to use the technology to develop a low-dose...
BC Week In Review | Jun 30, 2008
Company News

Pinnacle Biologics, AstraZeneca deal

AstraZeneca’s MedImmune Inc. subsidiary purchased an undisclosed amount in preferred convertible stock from Pinnacle. Further details were not disclosed. Pinnacle has exclusive rights to market and distribute MedImmune’s Ethyol amifostine in western Europe, Turkey and...
BC Week In Review | Feb 25, 2008
Company News

AstraZeneca, Pinnacle sales and marketing update

AstraZeneca's MedImmune Inc. subsidiary granted Pinnacle exclusive rights to market and distribute Ethyol amifostine in western Europe, Turkey and Israel. The chemoprotectant thiol drug is approved to reduce renal toxicity associated with administration of cisplatin...
BioCentury | Nov 20, 2006
Strategy

Biologics & more

Biologics & more Biologics & more Shantha manufactures and markets five follow-on biologics, as well as various Elisa and rapid test kits. The company also markets 17 in-licensed and generic products for oncology and infectious...
BC Week In Review | Nov 6, 2006
Clinical News

Ethyol amifostine regulatory update

MEDI filed a Citizen's Petition asking FDA to refuse to approve any ANDAs for generic amifostine with labeling that does not address the compound's use to reduce xerostomia in head and neck cancer patients being...
BC Extra | Oct 21, 2005
Financial News

MedImmune misses Street

MEDI reported a third quarter loss per share of $0.25, missing the consensus estimate of a loss of $0.22. In the same period last year, MEDI's loss was $0.22. The loss per share numbers exclude...
BC Extra | Oct 11, 2005
Company News

ODAC to review Phase IV commitments

FDA's Oncologic Drugs Advisory Committee will meet on Nov. 8 to review the status of Phase IV trials of seven products that were granted accelerated approval. The products include Doxil doxorubicin from Johnson & Johnson...
BioCentury | Sep 19, 2005
Strategy

MedImmune's selections

While sometimes dogged by the pro-blems it has faced with its FluMist influenza vaccine, MedImmune Inc. has been busy signing a slew of deals that will help to expand its pipeline of cancer, inflammation and...
BioCentury | Aug 8, 2005
Product Development

Chemoprotectant pathway

Protecting healthy cells from chemotherapy has long been a treatment goal, yet only one chemoprotectant is on the market - Ethyol amifostine from MedImmune Inc. Last week, Novelos Therapeutics Inc. reported data on an approach using...
Items per page:
1 - 10 of 123